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Global energy balance in mammals is controlled by
the actions of circulating hormones that coordinate
fuel production and utilization in metabolically active
tissues. Bone-derived osteocalcin, in its undercar-
boxylated, hormonal form, regulates fat deposition
and is a potent insulin secretagogue. Here, we
show that insulin receptor (IR) signaling in osteo-
blasts controls osteoblast development and osteo-
calcin expression by suppressing the Runx2 inhibitor
Twist2.Mice lacking IR in osteoblasts have low circu-
lating undercarboxylated osteocalcin and reduced
bone acquisition due to decreased bone formation
and deficient numbers of osteoblasts. With age,
these mice develop marked peripheral adiposity
and hyperglycemia accompanied by severe glucose
intolerance and insulin resistance. The metabolic
abnormalities in these mice are improved by infu-
sion of undercarboxylated osteocalcin. These results
indicate the existence of a bone-pancreas endocrine
loop through which insulin signaling in the osteoblast
ensures osteoblast differentiation and stimulates os-
teocalcin production, which in turn regulates insulin
sensitivity and pancreatic insulin secretion.
INTRODUCTION
Management of constant energy supply in an environment of
variable food intake is critical for the survival of all terrestrialspecies. To this end, mammals have evolved intricate networks
of local and circulating factors that coordinate energy expendi-
ture by communicatingmetabolic information between themajor
organs that produce, store, and utilize energy. The skeleton is
a highly metabolic tissue and is increasingly recognized as an
important player in the coordination of global energy utilization
through its hormonal interactions with other tissues (Fukumoto
andMartin, 2009; Lee and Karsenty, 2008). As an example, leptin
is a well characterized hormone produced by adipocytes that
influences insulin sensitivity (Yamauchi et al., 2001) and also
regulates postnatal bone acquisition (Karsenty, 2006). It is now
appreciated that leptin acts indirectly on bone by activating
sympathetic nerves whose efferent outputs target b2-adrenergic
receptors on osteoblasts to regulate their proliferation and differ-
entiation (Ducy et al., 2000; Takeda et al., 2002). Upregulation of
sympathetic tone by leptin has also been shown to inhibit insulin
secretion via a mechanism involving the osteoblast (Hinoi et al.,
2008).
Several lines of circumstantial evidence suggest that insulin
also impacts bone development and physiology by regulating
osteoblast function. First, a functional insulin receptor (IR) is
expressed by osteoblasts and exposure of primary osteoblasts
or osteoblast-like cell lines to physiological levels of insulin
increases bone anabolic markers including collagen synthesis
(Pun et al., 1989; Rosen and Luben, 1983), alkaline phosphatase
production (Kream et al., 1985), and glucose uptake (Ituarte
et al., 1989). Second, patients with Type-1 diabetes mellitus
(T1DM) can develop early onset osteopenia or osteoporosis
(Kemink et al., 2000; Thrailkill, 2000), and have an increased
risk of fragility fracture (Janghorbani et al., 2006; Nicodemus
and Folsom, 2001), as well as poor bone healing and regenera-
tion after injury (Loder, 1988). Analogous bone abnormalitiesCell 142, 309–319, July 23, 2010 ª2010 Elsevier Inc. 309
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Figure 1. Insulin Receptor Signaling Promotes Osteoblast Differentiation
(A) Immunohistochemical staining for insulin receptor (a) and an isotype control (b) in trabecular bone of the distal metaphysis. Filled arrows denote osteoblasts,
open arrows denote osteocytes. Muscle was used as positive control (c). All error bars represent standard error of the mean (SEM).
(B) Western blot analysis of the insulin receptor expression in primary osteoblasts isolated from IRflox/flox mice after infection with adenovirus expressing Cre or
GFP as a control. All error bars represent SEM.
(C) Quantification of osteoblast proliferation by BrdU uptake in control and DIR osteoblasts. All error bars represent SEM.
(D) Quantification of osteoblast apoptosis via Annexin V staining in control and DIR osteoblasts treated with 8 ng/ml staurosporine. All error bars represent SEM.
(E–G) Examination of osteoblast differentiation after the deletion of IR. (E) Alkaline phosphatase (ALP) and Alizarin Red (ARS) staining after 7 and 14 days of differ-
entiation, respectively. (F) RT-PCR analysis of IR, Runx2, ATF4, and osteocalcin (OCN) expression after 7 days of differentiation. (G) ALP and ARS staining after
culture in the presence or absence of 13 nM IGF-1. All error bars represent SEM.
(H) Osteocalcin promoter activity assessed in Mc3t3-E1 cells transfected with OC1050-Luc and treated with insulin for 6 hr. All error bars represent SEM.
(I) ChIP analysis of Runx2 binding to the osteocalcin promoter after 6 hr of 10 nM insulin treatment. All error bars represent SEM.
(J) ChIP analysis of Runx2 binding to the osteocalcin promoter in control and DIR osteoblasts. All error bars represent SEM.
(K) RT-PCR analysis of OCN and Runx2 expression in primary osteoblasts treated with 10 nM insulin for 6 hr. All error bars represent SEM.
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are observed in animal models of T1DM that also exhibit bone
loss (Herrero et al., 1998; Verhaeghe et al., 1990) due to reduced
bone formation (Goodman and Hori, 1984; Shires et al., 1981;
Verhaeghe et al., 1992; Verhaeghe et al., 1990). Localized insulin
delivery accelerates healing in these models by enhancing
osteogenesis (Gandhi et al., 2005).
For the hormonal networks described above to function effec-
tively, it is reasonable to suggest that signals emanating from the
osteoblast should regulate the action of both insulin and leptin.
Osteocalcin, a factor produced only by osteoblasts (Weinreb
et al., 1990), is a good candidate to fulfill such a function (Lee
et al., 2007). Similar to other hormones, osteocalcin is synthe-
sized as pre-pro-osteocalcin that is processed into pro-osteo-
calcin in the endoplasmic reticulum. Before being secreted
by osteoblasts, osteocalcin undergoes vitamin K-dependent
carboxylation on three Gla residues that endows the molecule
with high affinity for bone matrix. A small portion of osteocalcin
remains undercarboxylated and is secreted into the circulation
(Delmas et al., 1983). The undercarboxylated form of osteocalcin
has been proposed to act as a hormone that links bone to other
regulators of glucose homeostasis, including insulin and leptin
(Hinoi et al., 2008; Lee et al., 2007).
Previous attempts to demonstrate a biological role for insulin
in bone have been complicated by the potentially confounding
presence of IGF-1R in osteoblasts (Fulzele et al., 2007), which
activates intracellular signaling pathways common to those
activated by insulin. To circumvent this problem and to directly
examine the function of insulin signaling in bone, we engineered
mice lacking IR specifically in osteoblasts (Ob-DIR). Here we
show that mutant Ob-DIR mice accumulate less trabecular
bone due to a failure of osteoblast maturation and decreased
bone formation. With age, the Ob-DIR mice developed marked
peripheral adiposity and insulin resistance accompanied by
decreased circulating undercarboxylated osteocalcin. These
metabolic abnormalities were improved by infusion of exoge-
nous undercarboxylated osteocalcin. Our results suggest the
existence of a bone-pancreas endocrine loop through which
insulin signaling in the osteoblasts stimulates osteocalcin pro-
duction, which in turn regulates pancreatic insulin secretion to
control glucose homeostasis.RESULTS
IR Is Required for Osteoblast Proliferation, Survival,
and Differentiation
To begin to define specific actions of insulin in bone, we deter-
mined the cellular localization of IR in bone from mature wild-
type mice. IR immunoreactivity was abundant in osteoblasts
on trabecular bone surfaces but was low or absent in osteocytes
(Figure 1A). We next assessed the requirement of IR for osteo-
blast proliferation, survival, and differentiation in vitro. Primary(L) Microarray analysis of insulin-regulated genes 4-fold over- or underexpressed
ontology analysis (see also Table S1). All error bars represent SEM.
(M) Twist1 and Twist2 expression in DIGF-1R osteoblasts 24 hr after 10 nM insu
(N) Expression of regulators of Runx2 activity in control and DIR osteoblasts afte
(O) Coimmunoprecipitation of Runx2 and Twist2 in control and DIR osteoblasts.osteoblasts were isolated from the calvarial bones of newborn
IR floxedmice (Bruning et al., 1998) and infected with adenovirus
expressing Cre recombinase to disrupt IR expression (hereafter
referred to as DIR) or with adenovirus expressing GFP as a
control (Figure 1B). DIR osteoblasts had reduced BrdU incorpo-
ration (Figure 1C) and increased sensitivity to apoptotic signals
when examined by Annexin V staining (Figure 1D) compared to
controls. In addition, differentiation was severely impaired in
DIR osteoblasts, which accords with our previous studies that
demonstrated that insulin treatment increased markers for
osteoblast differentiation (Fulzele et al., 2007). Alkaline phospha-
tase and Alizarin Red staining after culture in osteogenic media
(consisting of 10% serum that contains insulin, 10mM b-glycerol
phosphate and 50 mg/ml ascorbic acid) were significantly
decreased in DIR osteoblasts when compared to controls (Fig-
ure 1E), and these deficiencies were accompanied by decreased
expression of Runx2 and osteocalcin mRNA (Figure 1F). Expo-
sure of IR-deficient osteoblasts to exogenous IGF-1, which
elicits downstream signaling events similar to insulin, did not
improve alkaline phosphatase expression or the degree ofmatrix
mineralization in DIR osteoblasts (Figure 1G).Insulin Promotes Osteoblast Differentiation
by Suppressing Twist2
The profound defect in differentiation observed in osteoblasts
lacking IR suggested that insulin signaling influences the expres-
sion or activity of a central regulator of the osteoblast differenti-
ation program. In this regard, Runx2 seemed an obvious candi-
date because the expression of this factor was decreased in
differentiating DIR osteoblasts (Figure 1F). Insulin treatment
induced a 3-fold increase in osteocalcin promoter activity (Fig-
ure 1H) and a 2.5-fold increase in Runx2 occupancy of the
OSE2 element when assessed by quantitative chromatin immu-
noprecipitation (Figure 1I). Further, Runx2 binding to the osteo-
calcin promoter was decreased in osteoblasts lacking the IR
(Figure 1J). However, although insulin induced a 6-fold increase
in osteocalcin mRNA expression, Runx2 expression was not
affected (Figure 1K). These data indicated that insulin regulates
Runx2 activity via an indirect mechanism.
To identify insulin-sensitive target genes that may influence
Runx2 in osteoblasts we profiled RNA isolated from insulin
treated DIGF-1R osteoblasts (used to eliminate the possibility
of IGF-1R cross-activation by insulin) by microarray (Affymetrix
Murine Genome 430–2.0). This analysis revealed 543 genes
that were positively and negatively regulated by 4-fold or greater
in response to 12 hr of insulin treatment (see Table S1 available
online), including 16 genes known to be involved in osteoblast
differentiation (Figure 1L). Among these, Twist2, an established
inhibitor of Runx2 activity (Bialek et al., 2004), was downregu-
lated. Separate studies in primary osteoblasts confirmed the
inhibition of Twist2 as well as Twist1 mRNA after treatmentand related to bone remodeling in DIGF-1R osteoblasts as identified by gene
lin treatment. All error bars represent SEM.
r 7 days of differentiation. All error bars represent SEM.
All error bars represent SEM.
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with insulin (Figure 1M). Conversely, disruption of IR upregulated
Twist2 and to a lesser extent Twist1 mRNA but did not alter other
established regulators of Runx2 activity (Figure 1N). Coimmuno-
precipitation experiments demonstrated a decrease in Runx2
protein levels and an increase in the fraction of Runx2 bound
by Twist2 in cells lacking IR (Figure 1O). Taken together, these
data suggest that insulin signaling regulates osteoblast differen-
tiation, in part, by suppression of the Runx2 inhibitor Twist2.
Mice Lacking IR in Osteoblasts Have Reduced Postnatal
Bone Acquisition
To determine the importance of insulin signaling in bone devel-
opment in vivo, we analyzed the skeletal phenotype of mice lack-
ing the IR in osteoblasts. Male progeny from matings between
OC-CreTG/+ IRflox/flox and IRflox/flox mice (Bruning et al., 1998)
with the genotype OC-CreTG/+ IRflox/flox (hereafter, referred to
as Ob-DIR) were selected for detailed analysis. Allele-specific
PCR performed on DNA isolated from tissues of Ob-DIR mice
revealed that recombination of IR alleles occurred only in skeletal
tissues (i.e., calvaria, femur, and vertebrae) (Figure 2A). Male
littermates lacking the OC-Cre transgene and, therefore, wild-
type for IR gene function served as controls.
The loss of IR in osteoblasts dramatically impaired postnatal
trabecular bone acquisition. Whereas control mice accumulated
trabecular bone to maximal levels by 6 weeks, mice lacking IR
failed to accumulate trabecular bone; trabecular bone volume
(BV/TV) was decreased by >47% in Ob-DIR mice compared to
controls at both 3 and 6 weeks of age (Figures 2B and 2C).
This defect in bone acquisition was characterized by significant
decreases in trabecular numbers (Tb. N, Figure 2D) and thick-
ness (Tb. Th, Figure 2E), and significant increases in trabecular
spacing (Tb. Sp, Figure 2F).
Static and dynamic histomorphometric analyses performed at
3 and 6 weeks of age showed that the decrease in bone volume
in Ob-DIR mice was secondary to a reduction in the number
of osteoblasts. Osteoblast numbers per bone perimeter (Ob.
N/BPM) in Ob-DIR mice were decreased by 79% at 3 weeks of
age (Figure 2G) and 47% at 6 weeks of age (Figure 2H) when
compared to controls. This decrease in osteoblast numbers was
accompanied by a 30% reduction in bone formation rate (BFR/
BS, 13.46 ± 2.02 versus 9.34 ± 0.92, mean ± standard error of
the mean [SEM], p = 0.06) at 6 weeks of age (Figure 2I). Osteo-
clast numbers per bone perimeter (Oc. N/BPM) were unchanged
in Ob-DIR mice when compared to controls (Figure 2J). How-
ever, erosion depth was decreased at 3 weeks of age in Ob-DIR
mice (Figure 2K), indicating a decrease in osteoclast activity.
Consistent with this, the serum levels of CTx were significantly
decreased (Figure 2L) in Ob-DIR mice and differentiating DIR
osteoblasts expressed significantly more Opg than controls
(Figure 2M). These histomorphometric data contrast to the
phenotype of mice lacking the IGF-1R that have increased oste-
oblast numbers and more bone matrix that is undermineralized
(Zhang et al., 2002). When considered together with our in vitro
data, these results suggest that IR is required for normal post-
natal bone acquisition, and that the bone phenotype in these
mice is likely due to a failure of normal osteoblast differentiation
resulting from increased Twist2 expression and a suppression of
Runx2.312 Cell 142, 309–319, July 23, 2010 ª2010 Elsevier Inc.Mice Lacking IR Develop Increased Adiposity
and Insulin Resistance
Ob-DIR mice had normal longitudinal growth but developed an
unanticipated increase in total body mass relative to control
littermates (Figures 3A and 3B). Measurements of body compo-
sition at 24 weeks by qMR revealed a 40% increase in fat mass
(Figure 3C) and an 8% decrease in lean mass in Ob-DIR mice
relative to controls (Figure 3D). At necropsy the weights of the
major fat pads were increased by 12 weeks in Ob-DIR mice
(Figure 3E) and were further increased at 24 weeks of age
(Figure 3F). The accumulation of peripheral fat did not result
from changes in feeding behavior as food intake, measured at
12 weeks, was similar in control and Ob-DIR mice (Figure 3G).
Indirect calorimetry demonstrated that Ob-DIR mice had
decreased rates of oxygen consumption comparedwith controls
(VO2, Figure 3H), without a change in the respiratory exchange
ratio (RER; Figure 3I). Thus, the decreased rate of oxidative
metabolism resulted in overall decreased rates of energy expen-
diture (Figure 3J). By contrast, body weights (Figures 3K and 3L)
and composition (Figures 3M and 3N) of mice lacking the IGF-1R
in osteoblasts were similar to control littermates.
The peripheral adiposity in Ob-DIR mice suggested that the
increase in body fat occurred secondary to alterations in glu-
cose homeostasis and/or insulin dynamics. In accordance with
this idea, nonfasting serum glucose levels were significantly
increased in Ob-DIR mice (Figure 4A), whereas serum insulin
(Figure 4B) was decreased. To assess total body sensitivity to
glucose and insulin, we performed standard glucose tolerance
test (GTT) and insulin tolerance test (ITT) at both the 12-week
and 24-week time points. Baseline, fasting-glucose concentra-
tions were similar in Ob-DIR and control mice. However, glucose
excursions in glucose-challenged Ob-DIR mice were signifi-
cantly higher than controls (Figures 4C and 4E). In addition,
insulin administration did not lower glucose concentrations to
the extent seen in control mice (Figures 4D and 4F).
The lower circulating insulin levels in nonfasted Ob-DIR mice,
together with their exaggerated glucose excursions (GTT) and
insulin insensitivity (ITT), suggested the development of insulin
resistance in the face of reduced insulin secretory reserves.
In accordance with this scenario, b cell area and mass were
decreased at 12 weeks (data not shown) and 24 weeks in
Ob-DIR mice when compared to controls (Figures 4G–4I), and
this was accompanied by reduced expression of Ins1 and Ins2
(Figure 4J). Additionally, the expression of gene markers for
insulin sensitivity was reduced in white and brown adipose
tissue, whereas genes associated with gluconeogenesis were
enhanced in the liver (Figures 4K–4O). Taken together, these
results suggest that loss of insulin signaling in osteoblasts results
in increased fat accumulation accompanied by both glucose
intolerance and target tissue insulin resistance.
Metabolic Dysregulation in Ob-DIR Mice Is Caused
by Reduced Undercarboxylated Osteocalcin
The accumulation of peripheral fat, glucose intolerance, and
insulin resistance, together with decreased insulin levels in the
Ob-DIR mice, are reminiscent of the alterations in serum bio-
chemistry and body composition seen previously in osteocalcin-
deficient mice (Lee et al., 2007). Moreover, osteoblast-derived
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Figure 2. Insulin Receptor Signaling Is Necessary for Postnatal Bone Acquisition
(A) PCR analysis of insulin receptor (IR) allele recombination in tissues for Ob-DIR mice. All error bars represent SEM.
(B–F) Quantitative micro-CT analysis of the distal femur in control and Ob-DIR mice at 3, 6, and 12 weeks of age (n = 4–5 mice). (B) Representative images. (C)
Bone volume/tissue volume, BV/TV (%). (D) Trabecular number, Tb. N (no./mm), (E) Trabecular thickness, Tb. Th (mm). (F) Trabecular spacing, Tb. Sp (mm). All error
bars represent SEM.
(G–K) Static and dynamic histomorphometric analysis of the distal femoral metaphysis in control and Ob-DIR mice at 3 and 6 weeks of age (n = 5–7 mice). (G)
Osteoblast Number per bone perimeter, Ob. N/BPM (no./100 mm) at 3 weeks of age. (H) Osteoblast Number per bone perimeter at 6 weeks of age. (I) Bone
formation rate per bone surface, BFR/BS, mm3/cm2/year. (J) Osteoclast number per bone perimeter, Oc. N/BPM (no./100 mm). (K) Erosion depth, EDE (mm).
All error bars represent SEM.
(L) Serum CTx (ng/ml). All error bars represent SEM.
(M) RankL and Opg expression in control and DIR osteoblasts after 7 days of differentiation. All error bars represent SEM.undercarboxylated osteocalcin is a potent secretogogue for
insulin (Ferron et al., 2008). These observations, together
with our current demonstration that insulin potently stimulatesosteocalcin expression in osteoblasts, suggested the possi-
bility that osteocalcin might function as a circulating factor
responsible for the increased fat accumulation and changesCell 142, 309–319, July 23, 2010 ª2010 Elsevier Inc. 313
Figure 3. Ob-DIR Mice, but Not Ob-DIGF-1R Mice, Have Increased Peripheral Adiposity
(A–E) Assessment of body composition in control and Ob-DIRmice (n = 5–7mice). (A) Body weight. (B) Representative DEXA images at 24 weeks. (C) Fat mass by
qMR. (D) Lean mass by qMR. (E) Mass of individual fat pads at 12 weeks. All error bars represent SEM.
(F) Mass of individual fat pads at 12 weeks. All error bars represent SEM.
(G) Food intake over 4 days at 12 weeks (n = 4). All error bars represent SEM.
(H and I) Indirect calorimetry at 12 weeks (n = 4). (H) VO2 (ml/kg/hr). (I) Respiratory exchange ratio (RER). All error bars represent SEM.
(J) Energy expenditure (kcal/kg/hr). All error bars represent SEM.
(K–N) Assessment of body composition in control and Ob-DIGF-1R mice at 24 weeks of age (n = 5–11 mice). (K) Representative DEXA images. (L) Body weight.
(M) Fat mass by qMR. (N) Lean mass by qMR. All error bars represent SEM.
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Figure 4. Ob-DIR Mice Are Insulin Insensitive and Glucose Intolerant
Measurements of nonfasted (A) serum glucose and (B) serum insulin in 12- and 24-week-old control and Ob-DIR mice (n = 4–5 mice). Glucose tolerance test after
fasting overnight at (C) 12 weeks and (E) 24 weeks (n = 4–6 mice). Insulin tolerance test after fasting for 4 hr at (D) 12 weeks and (F) 24 weeks (n = 4–6 mice). (G–I)
Histomorphometric analysis of pancreatic b cells in control and Ob-DIR mice (n = 4–5 mice). (G) Representative images of islets stained for insulin. (H) b cell area.
(I) b cell mass. (J–M) qPCR in tissues isolated from control and Ob-DIR mice (n = 3). (J) Ins1 and Ins2 expression in pancreas. (K) Pparg expression in white
adipose. (L) UCP1 expression in brown adipose. (M) Pck1 and G6pase expression in the liver. All error bars represent SEM.in insulin sensitivity in the Ob-DIR mice. To investigate this
possibility, we measured total and undercarboxylated osteocal-
cin in the serum of control and Ob-DIR mice. Total and under-
carboxylated osteocalcin serum levels were decreased signifi-
cantly in the Ob-DIR mice compared to controls (Figures 5A
and 5B, respectively). Total and undercarboxylated osteocalcin
levels were also lower in conditioned media of DIR osteoblasts
than in that of controls (Figures 5C and 5D, respectively), sug-
gesting that the lower levels of undercarboxylated osteocalcin
in Ob-DIR mice were not related to renal clearance (Delmas
et al., 1983).To provide additional evidence that osteocalcin deficiency
underlies the metabolic disturbances in the Ob-DIR mice, we
measured the effect of a two-week infusion of undercarboxy-
lated osteocalcin on glucose and insulin sensitivity measured
by GTT and ITT. When infused with undercarboxylated osteocal-
cin and challenged with glucose, Ob-DIR mice had blunted
glucose excursions and more pronounced reductions in serum
glucose after a bolus of insulin relative to controls, indicating
an improved sensitivity to insulin (Figures 5E and 5F). Collec-
tively, these results suggest a model in which insulin signaling
in osteoblasts activates transcriptional events that promoteCell 142, 309–319, July 23, 2010 ª2010 Elsevier Inc. 315
Figure 5. Undercarboxylated Osteocalcin Improves Glucose Tolerance and Insulin Sensitivity in Ob-DIR Mice
Measurements of (A) total and (B) undercarboxylated osteocalcin in the serum of 24-week-old control and Ob-DIR mice (n = 5 mice). (C) Total and (D) undercar-
boxylated osteocalcin in media conditioned by control and DIR osteoblasts. (E) Glucose tolerance test and (F) insulin tolerance test in Ob-DIR mice infused with
saline or undercarboxylated osteocalcin (30 ng/g BW/h) for 2 weeks (n = 3). (G) Model for the regulation of bone acquisition and body composition by insulin.
Insulin signaling stimulates osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2. Undercarboxylated osteocal-
cin increases tissue insulin sensitivity and insulin secretion. All error bars represent SEM.osteoblast differentiation and control the production and bio-
availability of osteocalcin. The undercarboxylated form of osteo-
calcin, in turn, acts as a circulating hormone to regulate fat
accumulation and insulin production and sensitivity (Figure 5G).
DISCUSSION
In this study,weuncovered twopreviouslyunappreciated roles for
insulin in bone that are both achievedby the ability of the hormone
to activate a common osteoblast transcriptional pathway. First,
insulin suppresses the Runx2 inhibitor Twist2, which promotes
osteoblast differentiation necessary for normal bone formation.
Second, insulin induces production of the insulin secretagogue
osteocalcin, which influences glucose utilization. These results
suggest the existence of a novel endocrine regulatory loop in
which insulin signaling in the osteoblast controls postnatal bone
development and simultaneously regulates insulin sensitivity
andpancreatic insulin secretion to regulate glucose homeostasis.
Insulin Regulates Osteoblast Function and Postnatal
Bone Acquisition
The reduced bone mass and osteoblast numbers in the Ob-DIR
mice, together with the lower proliferation and differentiation316 Cell 142, 309–319, July 23, 2010 ª2010 Elsevier Inc.capacity of IR-deficient osteoblasts in vitro, demonstrate that
insulin signaling is critical for osteoblast function. This bone
phenotype is strikingly different from that observed in mice lack-
ing the IGF-1R in osteoblasts, which exhibit normal or even
elevated numbers of mature osteoblasts (Zhang et al., 2002).
Transcriptional profiling and immunoprecipitation experiments
conducted in insulin-treated DIGF-1R osteoblasts indicated that
insulin signaling regulates osteoblast differentiation by suppres-
sion of Twist2, a known inhibitor of Runx2 (Bialek et al., 2004).
Precisely how IR signaling is coupled to transcriptional control
of osteoblast function deserves further study. A good candidate
is the forkhead protein FoxO1 that is known to be downstream of
IR and serves to suppress insulin action in many target tissues
(Accili and Arden, 2004; Kitamura et al., 2002; Nakae et al.,
2002, 2003). FoxO1 activity is associated with decreased prolif-
eration and increased sensitivity to apoptosis inducing signals
(Paik et al., 2007), a phenotype identical to that observed in oste-
oblasts lacking IR, which should have increased FoxO1 activity.
Unfortunately, firm conclusions regarding potential IR/FoxO1
interactions in bone cannot be made due to the fact that a large
percentage ofmice lacking FoxO1 in osteoblasts die shortly after
birth (Rached et al., 2010). However, the portion of mice lacking
FoxO1 in osteoblasts that survive have increased glucose
tolerance and increased insulin sensitivity, metabolic features
opposite from the Ob-DIR mice described in this paper.
Our findings of reduced trabecular bone in the Ob-DIR mice
contrast to previous reports of normal bone mass in a mouse
globally deficient in IR (Irwin et al., 2006). In thesemice, postnatal
lethality due to ketoacidosis was genetically rescued by trans-
genic re-expression of the IR in the pancreas, liver, and brain
(tTr-IRKO mice) (Okamoto et al., 2004). However, because
bone volume in these mice was measured at a single time point
(6 months) we suspected that changes in bone mass due to loss
of the insulin receptor might have been missed, particularly
because the changes observed in our Ob-IR-deficient mice
were most pronounced at early postnatal time points. Micro-
CT measurements in these mice conducted by our laboratory
revealed a reduced trabecular bone volume compared to control
animals at 3weeks of age (data not shown). Therefore, the loss of
IR in osteoblasts in two mouse models created using different
genetic strategies produced a remarkably similar bone pheno-
type, thus confirming the importance of IR in normal bone
acquisition.
In addition to controlling osteocalcin gene transcription, insulin
also appears to regulate posttranslational modification of osteo-
calcin because the proportion of undercarboxylated osteocalcin
was decreased in both the conditioned media from IR null differ-
entiated osteoblasts and in serum from Ob-DIR mice. Neither of
these events were observed in osteoblasts exposed to IGF-1,
clearly indicating that insulin and not IGF-1 is a primary regulator
of osteocalcin mRNA expression and possibly posttranslational
processing. Also, whereas loss of IGF-1R in osteoblasts could
be partially rescued by insulin (Fulzele et al., 2007), osteoblasts
lacking IR were not rescued by IGF-1. Together, these results
indicate that signals derived from the IR are even more critical
for osteoblast development than those generated by IGF-1 and
cannot be compensated by other factors at least during early
bone development.
Insulin Stimulates Osteocalcin to Regulate
Glucose Homeostasis
The metabolic phenotype in mice lacking IR in their osteoblasts
suggests the development of tissue resistance to insulin coupled
with deficient insulin secretory reserves, a phenotype virtually
identical to that observed in osteocalcin-deficient mice (Lee
et al., 2007). These observations fit with an emerging body of
data that implicate circulating undercarboxylated osteocalcin
as a bone-derived hormone that helps coordinate glucose
homeostasis and body composition (Lee and Karsenty, 2008).
Thus, osteocalcin induces insulin production by pancreatic
b cells and adiponectin secretion from adipocytes (Lee et al.,
2007). Moreover, osteocalcin increased basal and insulin stimu-
lated glucose transport in adipocytes (Ferron et al., 2008). The
current study identifies insulin as a critical regulator of osteocal-
cin production. Levels of osteocalcin were reduced in serum of
Ob-DIR knockout mice and medium conditioned by their osteo-
blasts. Moreover, the observation that infusion of osteocalcin
improved glucose tolerance and insulin sensitivity strongly
suggests that the metabolic and body composition alterations
in the Ob-DIR mice are due to the loss of insulin’s ability to stim-
ulate osteocalcin expression in osteoblasts.The hormonal activity of osteocalcin with respect to its secre-
tion and actions on fat and pancreas appear to be regulated
by posttranslational g-carboxylation that we predict is also
controlled by insulin. In this regard, the percentage of circulating
undercarboxylated osteocalcin was decreased in the Ob-DIR
mice. We anticipated that insulin might control g-carboxylation
of osteocalcin by regulating osteotesticular protein tyrosine
phosphatase (OST-PTP), the product of the Esp gene known
to be required for osteocalcin carboxylation (Lee et al., 2007).
Thus, Esp-deficient mice produce more undercarboxylated
osteocalcin and exhibit increased insulin secretion, hypogly-
cemia, and increased insulin sensitivity, whereas overexpression
of Esp produces the opposite phenotype. It should be noted,
however, that a homolog for the Esp gene has so far not been
identified in humans. Therefore, other genes and/or mecha-
nisms, such as vitamin K-dependent g-carboxylase, are likely
to play a role in the regulation of osteocalcin g-carboxylation
by insulin.
Although additional studies will be required to fully establish
the exact physiological relevance of our findings, several existing
studies in humans are consistent with the insulin-osteocalcin
endocrine loop suggested here. Serum levels of undercarboxy-
lated osteocalcin correlate with improved glucose tolerance in
men (Hwang et al., 2009). Moreover, serum osteocalcin concen-
trations have been found to be inversely associated with blood
markers of dysmetabolic phenotype and measures of adiposity
(Pittas et al., 2009). On a more fundamental level, our work
supports a growing body of data that indicates that the skeleton
plays an integrative role in regulating energy expenditure and fuel
utilization (Karsenty, 2006).
In summary, the results presented in this paper suggest the
existence of a novel bone-pancreas feedback loop through
which insulin signaling in the osteoblast promotes postnatal
bone acquisition and simultaneously stimulates osteocalcin pro-
duction, which in turn, regulates pancreatic insulin secretion to
control glucose homeostasis. These observations should have
immediate impact on our understanding of the global control of
energy balance and theoretically guide new approaches for
treatment of bone disease and diabetes.EXPERIMENTAL PROCEDURES
Animal Models
All procedures involving mice were approved by the Institutional Animal Care
and Use Committee of the University of Alabama at Birmingham and Johns
Hopkins University. Mice lacking IR in osteoblasts were generated by crossing
osteocalcin-Cre (OC-Cre) transgenic mice (Zhang et al., 2002) with IRflox/flox
mice (Bruning et al., 1998). The following primer pairs that amplify exons 3–5
were used to assess tissue-specific recombination: 50-GCTGCACAGCT
GAAGGCCTGT-30 and 50-CTCCTCGAATCAGATGTAGCT-30. Ob-DIGF-1R
mice have been described previously (Zhang et al., 2002). Genotyping strate-
gies are available upon request.
Culture of Primary Osteoblasts
Osteoblasts were isolated from calvaria of newborn mice by serial digestion in
1.8 mg/ml of collagenase. For in vitro deletion of the IR and IGF-1R, osteo-
blasts containing floxed alleles were infected with adenovirus encoding Cre
recombinase or green fluorescent protein (Vector Biolabs) as previously
described (Fulzele et al., 2007). Infection with 100 mulitiplicity of infection
was used in all experiments. Osteoblast differentiation was induced byCell 142, 309–319, July 23, 2010 ª2010 Elsevier Inc. 317
supplementing aMEM media with 10% serum (that contains insulin), 10 mM
b-glycerol phosphate, and 50 mg/ml ascorbic acid. Alkaline phosphatase
and Alizarin Red S staining were carried out according to standard techniques.Gene Expression Studies
Total RNA was extracted using TriZol, reverse transcribed using iScript cDNA
Synthesis Kit (Bio-Rad), and amplified by real-time PCR using SYBR GREEN
PCR Master Mix (Bio-Rad). Primer sequences were from PrimerBank (http://
pga.mgh.harvard.edu/primerbank/index.html). For microarray analysis, RNA
was hybridized to Affymetrix Murine Genome 430-2.0 Array chips and subse-
quently analyzed at the Microarray Core Facility at University of Alabama at
Birmingham. Data have been deposited in NCBI’s Gene Expression Omnibus
(accession number GSE21710). Antibodies for IR, IGF-1R, and Twist2 were
obtained from Santa Cruz. Mc3t3-E1 cells were transfected with the
OC1050-Luc using Lipofectamine 2000 (Invitrogen). Chromatin immunopre-
cipitation was performed using the Magna ChIP A kit (Millipore) with a Runx2
antibody obtained from MBL International.Imaging and Histomorphometry
Male control and Ob-DIR mice were sacrificed at the indicated age and bone
volume in the distal femoral metaphysis was assessed using a desktop micro-
tomographic imaging system (MicroCT40; ScancoMedical). Histological anal-
yses, using a semi-automatic method (Osteoplan II, Kontron) were carried out
on 3- and 6-week-old mice injected with 1% calcein (w/v) 3 and 2 days before
sacrifice, and 5 and 3 days before sacrifice, respectively (Zhang et al., 2002).
Histomorphometric parameters follow the recommended nomenclature of the
American Society of Bone and Mineral Research (Parfitt et al., 1987). Body
composition was measured by DEXA (Lunar PIXImus II GE Healthcare) and
qMR (3-in-1 Composition Analyzer, Echo Medical Systems) at 24 weeks of
age. Pancreata were fixed and stained, and islet morphometry was performed
as previously described (Hussain et al., 2006). IR expression was examined in
mouse long bones using an antibody from Upstate Biotechnology after tissue
was fixed in 10% buffered formalin, decalcified in 10% Na2EDTA, paraffin
embedded, and then processed for immunostaining according to standard
techniques.Metabolic Studies and Bioassays
For glucose tolerance test, glucose (1.5 g/kg BW) was injected IP after an over-
night fast. For insulin tolerance test, mice were fasted for 4 hr and then injected
IP with insulin (0.2 U/kg BW). Glucose was measured using a Glucose 201
analyzer (Hemocue, Lake Forest, CA, USA). For serum chemistries, insulin
and glucoseweremeasuredwith the EktachemDT II System (Johnson & John-
son Clinical Diagnostics). Indirect calorimetry was conducted in a open-flow
indirect calorimeter (Oxymax Equal Flow System; Columbus Instruments).
Calorimetry, daily body weight and daily food intake data were acquired during
a 4 day experimental period. Data from the first 3 days was used to confirm
acclimation to the calorimetry chamber, and the fourth day was used for anal-
yses. Rates of oxygen consumption (VO2, ml/kg/hr) and carbon dioxide
production (VCO2) were measured for each chamber every 8 min throughout
the study. Respiratory exchange ratio (RER = VCO2/VO2) was calculated by
Oxymax software (v. 4.02) to estimate relative oxidation of carbohydrate
(RER = 1.0) versus fat (RER approaching 0.7), not accounting for protein oxida-
tion. Energy expenditure was calculated as EE = VO23 (3.815 + (1.2323RER))
(Lusk, 1928), and normalized for subject body mass (kcal/kg/hr). Osteocalcin
levels were measured by IRMA assay (Immunotopics). Hydroxyapatite resin,
which binds the carboxylated form, was used to assess percentages of
carboxylated and undercarboxylated osteocalcin (Lee et al., 2007). Bacterially
produced mouse recombinant undercarboxylated osteocalcin or saline
control was infused at 30 ng/g BW/h using Alzet mini-osmotic pumps im-
planted subcutaneously (Ferron et al., 2008).Statistics
All results are presented as means ± standard errors of the mean. Statistical
analyses were performed using unpaired, two-tailed Student’s t or ANOVA
tests followed by post hoc tests. In all figures, *% 0.05.318 Cell 142, 309–319, July 23, 2010 ª2010 Elsevier Inc.ACCESSION NUMBERS
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